Arrowhead Pharmaceuticals, Inc. (ARWR)

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arrowhead Pharmaceuticals, Inc. ("Arrowhead" or "the Company") (NASDAQ: ARWR). Investors who purchased Arrowhead securities are encouraged to obtain additional information and assist the investigation.

 

The investigation concerns whether Arrowhead and certain of its officers and/or directors have violated federal securities laws.

 

On February 17, 2022, Arrowhead issued a press release announcing “interim results from AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC).”  Although characterizing the results as “positive”, Arrowhead disclosed that “[f]ive serious AEs [adverse events] in 5 patients were reported by investigators as possibly drug related, including myocarditis (in a patient with a history of TKI induced cardiomyopathy), demyelinating neuropathy (in a patient with autoimmune sequelae due to checkpoint inhibitors), chronic inflammatory demyelinating polyradiculoneuropathy (in a patient with distant history of checkpoint inhibitor use), hypoxia (in a patient with a pulmonary infiltrate), and acute hypoxemic respiratory failure (in a patient with progressive lung metastatic disease).”  On this news, Arrowhead’s stock price fell sharply during intraday trading on February 17, 2022.

 

If you are aware of any facts relating to this investigation or purchased Arrowhead shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.